TCG Crossover Management »

Inhibrx shares owned by TCG Crossover Management

Quarter-by-quarter ownership of Inhibrx (INBX) shares owned by TCG Crossover Management from 13F filings

Historical chart of TCG Crossover Management investment in Inhibrx

Tip: Access up to 7 years of quarterly data

All positions including Inhibrx held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibrx by TCG Crossover Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $32M 1.8M 18.35

More positions owned by TCG Crossover Management

Structure Therapeutics Adrs (GPCR)
Cogent Biosciences Comm (COGT)
Geron Corp Comm (GERN)
AN2 Therapeutics Comm (ANTX)
Savara Comm (SVRA)
Taysha Gene Therapies Comm (TSHA)
Kalvista Pharmaceuticals Comm (KALV)
Inhibrx Comm (INBX)
Aerovate Therapeutics Comm (AVTE)
Icosavax Comm
Compass Pathways Adrs (CMPS)
Ventyx Biosciences Comm (VTYX)
Tyra Biosciences Comm (TYRA)
Madrigal Pharmaceuticals Comm (MDGL)
Silence Therapeutics Adrs (SLN)

View all positions for TCG Crossover Management

Top funds holding Inhibrx

Viking Global Investors
RA Capital Management
Perceptive Advisors
Vanguard Group
Arrowpoint Asset Management
Bank of America Corporation
Logos Global Management
Partner Fund Management
Russell Investments
Citadel Advisors
Caption Management
Millennium Management
Charles Schwab Investment Management
Sphera Funds Management
Two Sigma Advisers

View all funds holding Inhibrx